NCT03042468View on ClinicalTrials.gov

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

August 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

177Lu-PSMA-617

177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)

DRUG

68Ga-PSMA-HBED-CC

68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging

Trial Locations (2)

10021

Weill Cornell Medical College, New York

70112

Tulane Cancer Center Clinic, New Orleans

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT03042468 - Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | Biotech Hunter | Biotech Hunter